Pediatrics CME

Discover New Guidelines with Online CME

This online CME program — tailored to anesthesiologists who care for patients of all ages in ambulatory and inpatient settings — provides a general review of common pediatric anesthesia challenges, as well as clinical pearls and procedure-specific considerations for the young patient.

Led by University of Minnesota’s Jakob Guenther, MD, expert speakers in Pediatric Anesthesia for General Anesthesiologists discuss physiology, pharmacology, preoperative/postoperative considerations, congenital heart defects, pain control, airway management, and more.

Additional continuing medical education lectures focus on frequent procedures and anesthetic challenges associated with specific specialties (ENT, dental, neurosurgery, urology, orthopedics, etc).

Learning Objectives

At the completion of this course, you should be able to:

• Have a better overview about the differences in physiology, pharmacology and anatomy between adult and pediatric patients including more recent data and evidence for your daily practice, both for basic techniques of pediatric anesthesia, as well as procedure specific strategies
• Approach pediatric patients with a focus on their specific needs in the preoperative (anxiety, agitation), intraoperative (physiology, fluid requirements, airway management) and postoperative (emergence, PO(N)V, airway complication) setting
• Have guidance how to optimize anesthetic technique for common procedures and conditions
• Have more background information about invasive and complex procedures, conditions (congenital heart disease) and interventions. Those procedures may not be part of your practice, but that the patient either went through them or will have to go through them in the future. Both past and future interventions may have implications on how to approach the patient’s anesthetic management while the patient is under your care

Intended Audience

This activity is designed for anesthesiology residents, pediatric anesthesia fellows, and general anesthesiologists.

Discover New Guidelines with Online CME

This online CME program — tailored to anesthesiologists who care for patients of all ages in ambulatory and inpatient settings — provides a general review of common pediatric anesthesia challenges, as well as clinical pearls and procedure-specific considerations for the young patient.

Led by University of Minnesota’s Jakob Guenther, MD, expert speakers in Pediatric Anesthesia for General Anesthesiologists discuss physiology, pharmacology, preoperative/postoperative considerations, congenital heart defects, pain control, airway management, and more.

Additional continuing medical education lectures focus on frequent procedures and anesthetic challenges associated with specific specialties (ENT, dental, neurosurgery, urology, orthopedics, etc)

Learning Objectives

At the completion of this course, you should be able to:

• Have a better overview about the differences in physiology, pharmacology and anatomy between adult and pediatric patients including more recent data and evidence for your daily practice, both for basic techniques of pediatric anesthesia, as well as procedure specific strategies
• Approach pediatric patients with a focus on their specific needs in the preoperative (anxiety, agitation), intraoperative (physiology, fluid requirements, airway management) and postoperative (emergence, PO(N)V, airway complication) setting
• Have guidance how to optimize anesthetic technique for common procedures and conditions
• Have more background information about invasive and complex procedures, conditions (congenital heart disease) and interventions. Those procedures may not be part of your practice, but that the patient either went through them or will have to go through them in the future. Both past and future interventions may have implications on how to approach the patient’s anesthetic management while the patient is under your care

Intended Audience

This activity is designed for anesthesiology residents, pediatric anesthesia fellows, and general anesthesiologists.

Your MDCalc CME subscription includes 15 AMA PRA Category 1 Credits™, with up to 11.5 credits available in the Pediatrics specialty.

Easily earn and redeem CME as you use review CME eligible calculator content. Over 1 million medical professionals use MDCalc’s over 550 tools daily to support clinical decision making at the bedside. Earn CME with the following Pediatrics calculators:

• AAP Pediatric HTN Guidelines
• Alvarado Score
• APGAR Score
• Bacterial Meningitis Score
• CATCH Rule
• FeverPAIN Score
• Paradise Criteria
• Pediatric Appendicitis Score (PAS)
• Peds NEXUS II Head CT Decision Instrument
• Rule of 7s
• Steroid Conversion
• Westley Croup Score

The BoardVitals Pediatric MOC Question Bank and Recertification Test Prep has over 1400 Pediatric MOC Recertification questions targeted to the ABP exam guidelines. Each question has an answer and detailed explanation, as well as an indicator of the percentage of Pediatricians who answered the question correctly. Like the Pediatric MOC exam itself, the Board Vitals question bank is focused on clinical knowledge.

The BoardVitals Pediatric MOC Question Bank and Recertification Test Prep features:
• Pediatric practice tests in review mode or timed mode
• Individually suggested content based on your strengths and weaknesses using Computer Adaptive Testing
• Each question is reviewed and rated by other Pediatricians
Pediatricians preparing for initial certification should see the Board Vitals Pediatrics Board Review Question Bank and Study Program.

Target Audience:
Pediatricians preparing for the Maintenance of Certification exam.

The Cleveland Clinic Ultrasound Workshop focuses on developing foundational diagnostic and procedural skills that can be quickly applied to clinical practice. Physicians, physician assistants and nurse practitioners across multiple specialties will benefit from lectures and demonstrations from more than twenty expert educators. This activity will provide a greater understanding of ultrasound as an imaging and interventional tool. As such, the lessons learned should have a direct impact on patient care. Worth 9.5 AMA PRA Category I Credits™, with ANCC and AAPA accreditation provided as well!

Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurodevelopmental disorder that has been diagnosed in up to 10% of school-age children in the US and frequently persists into adulthood. A study in a large Danish cohort found that ADHD was associated with higher mortality rates in children, adolescents, and adults, mainly due to accidents. Pharmacologic treatment of ADHD in children has been reported to decrease the risk of substance abuse in adolescents, and use of ADHD medications in adults has been associated with a reduced risk of serious traffic accidents and criminal behavior. This activity discusses how to reduce the risk of ADHD with PTBM and drugs approved by the FDA for treatment of ADHD.

Cystic Fibrosis (CF) is a genetic disease that affects nearly 70,000 people worldwide with more than 90% of patients diagnosed of Caucasian descent and a median lifetime survival remains a mere 43.6 years. CF is caused by an autosomal recessive mutation in the CF transmembrane regulator (CFTR) gene, which controls the other chloride and sodium channels at the cell surface and is found in the lungs, liver, pancreas, intestine, sweat duct, and epididymis. The primary organs in which the disease manifests clinically are the pancreas, leading to malabsorption of nutrients, and the lungs due to the accumulation of thick, sticky mucous that contributes to airway obstruction. CF causes several clinical complications, including recurrent pulmonary infections, nasal polyps, CF-related diabetes, fat-soluble vitamin deficiencies, acid reflux, and liver failure.

Target Audience:

The following HCPs: pulmonologists, pediatricians, gastroenterologists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in the aforementioned areas of specialty; and any other healthcare professionals with an interest in or who clinically encounter patients with CF.

By the end of the session the participant will be able to:

• Describe the pathophysiology of CF such that it might inform treatment mechanisms.
• Identify the currently available and emerging pharmacotherapeutic treatments for the management of CF and apply them to patient cases using evidence-based medicine.
• Describe newly approved and investigational therapies in development for CF.
• Evaluate an ongoing treatment plan for a specific patient with CF to optimize safety and efficacy, suggesting modifications for improvement, including the management of complications.

Hemophilia is a genetic disease caused by mutation of one of the genes for coagulation proteins leading to dangerous, uncontrolled bleeding. In hemophilia B, a mutation in the gene for factor IX (FIX) leads to an endogenous deficiency in the clotting factor. The incidence of hemophilia B is the same in all geographic regions, populations, and ethnic groups,affecting approximately 1 out of every 30,000 male births. The condition is diagnosed by measuring FIX activity, and patients with severe hemophilia have levels of 1% or less.

Patients with severe hemophilia B are at risk for spontaneous, life-threatening bleeding episodes. Untreated, the life expectancy is approximately 20 years,and painful or even life-threatening morbidities include intracranial hemorrhage, severe bleeding in other organ systems, musculoskeletal injury, and joint injury. In contrast, in people with moderate or mild hemophilia, abnormal bleeding usually occurs after minor trauma or surgery.

Physical therapy can ease symptoms if internal bleeding has damaged a patient’s joints, and surgery may be necessary if internal bleeding has caused severe damage. However, the current standard of therapy for hemophilia B is intravenous infusion of therapeutic factor concentrates. Through the reduction in the number of bleeding incidences and improvement in quality of life, factor replacement therapy has significantly reduced the morbidity and mortality of hemophilia. Furthermore, prophylactic therapy has the demonstrated benefit of reducing the development of hemophilic arthropathy.

Target Audience:

The following healthcare professionals: hematology, primary care physicians, and pediatricians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in hematology as well as other Hemophilia Treatment Center HCPs; and any other clinicians with an interest in hemophilia B.

By the end of the session the participant will be able to:

• Describe the risk factors and occurrence of hemophilia B.
• Identify available prophylactic and treatment options for hemophilia B and apply them to a patient case.
• Identify the new treatment options for hemophilia B.
• Identify adherence barriers in and deliver effective treatment counseling to patients with hemophilia B.

Hemophilia is a genetic disease caused by mutation of one of the genes for coagulation proteins leading to dangerous, uncontrolled bleeding. In hemophilia A, a mutation in the gene for factor VIII (FVIII) leads to an endogenous deficiency in the clotting factor. The incidence of hemophilia A is the same in all geographic regions, populations, and ethnic groups, affecting approximately 1 out of every 5000 male births. The condition is diagnosed by measuring FVIII activity, and patients with severe hemophilia have FVIII activity of 1% or less. Patients with severe hemophilia A are at risk for spontaneous, life-threatening bleeding episodes. Untreated, the life expectancy is approximately 20 years, and painful or even life-threatening morbidities include intracranial hemorrhage, severe bleeding in other organ systems, musculoskeletal injury, and joint injury. In contrast, in people with moderate or mild hemophilia, abnormal bleeding usually occurs after minor trauma or surgery.

Target Audience:

The following healthcare professionals: hematology, primary care physicians, and pediatricians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in hematology as well as other Hemophilia Treatment Center HCPs; and any other clinicians with an interest in hemophilia A.

By the end of the session the participant will be able to:

• Describe the risk factors and occurrence of hemophilia A.
• Identify available prophylactic and treatment options for hemophilia A and apply them to a patient case.
• Identify the new treatment options for hemophilia A.
• Identify adherence barriers in and deliver effective treatment counseling to patients with hemophilia A.

EQIPP courses help you identify and close gaps in your practice using practical tools while earning CME credit and meeting MOC Part 4: Performance in Practice requirements all at once. Each course requires some work online and offline and can be completed within 4-8 months, depending on the number of improvement cycles you implement to reach your goals.

Popular activities include:
• Give Your Immunization Rates a Shot in the Arm
• Bright Futures
• Medical Home for Pediatric Primary Care
• Eliminate Tobacco Use and Exposure
• Safe and Healthy Beginnings

Target Audience: Pediatricians, Family Physicians